Events

Daiichi Sankyo is honored to be a Platinum sponsor of LabCentral, a top-tier, shared laboratory space in Cambridge, Massachusetts, designed to serve as a launchpad for life science and biotech startups. In 2024, Daiichi Sankyo awarded credits to two biotech organizations engaging in unique technology platforms. This year, Daiichi Sankyo will award another two Golden Tickets to further support and celebrate innovative life-science companies. The recipient of the Golden Ticket will receive a $50,000 credit towards space and services at LabCentral’s flagship site at 700 Main Street in Cambridge, for use within a 13-month period. Additionally, Daiichi Sankyo will offer access to its team of skilled experts, who can provide guidance and feedback to early-stage companies.

2025 Daiichi Sankyo Autumn Golden Ticket Contest at LabCentral

Daiichi Sankyo is thrilled to announce that it is now accepting  applications for the 2025 Daiichi Sankyo Autumn Golden Ticket, inviting startups that are developing innovative technologies and therapeutics in the following areas to apply:

• Modality & Technology Areas:
• Drug delivery technology to specific organs or cell types
• Proximity inducing modalities
• RNA targeting therapeutics
• Modality for novel in vivo engineering
• Modality for protein upregulation/activation
• Modality inducing tissue/cell predilection
• De novo design of biologics with unique function or targeting
• Oncology Areas:
• Novel tumor-specific therapeutic modalities with unique approach or mechanism
• Unique methods for discovering tumor-specific binder
• Non-oncology Areas:
• Novel research for identifying disease-modifying targets using patient tissue samples and/or clinical data in central nerve system, cardiovascular, and ophthalmology
• Novel in vitro and in vivo models that recapitulate human pathological mechanisms/conditions 

Novel medical device, diagnostics and modality manufacturing are out of scope in 2025 Daiichi Sankyo Autumn Golden Ticket. 

How to Apply:

To apply, please send a non-confidential pitch deck (up to 20 pages), as a PDF, showcasing your innovative approach to advancing therapies for patients with high unmet needs to: GoldenTickets2025@daiichisankyo.com 

All submissions will be reviewed. Finalists will be invited to a pitch event at LabCentral in Cambridge, MA, where the Golden Ticket winners will be announced!

Timelines:

• Application submission opens: August 1, 2025
• Application deadline: September 22, 2025
• Golden Ticket finalists notified: October 19, 2025
• Daiichi Sankyo Autumn Golden Ticket Pitch Event and announcement of winners: November 19, 2025

Disclosures:

The winner of the Golden Ticket will receive a $50,000 credit towards space and services at LabCentral’s site at 700 Main Street in Cambridge, MA, for use within a 13-month period from the date the winner is offered available lab space. Additional terms and conditions apply, as determined by Daiichi Sankyo and LabCentral. Please visit https://www.labcentral.org/about/golden-tickets to learn more about the process and criteria. All submissions will be reviewed. The recipient will not receive any cash consideration. Those seeking access to, and discussions with, Daiichi Sankyo employees for guidance or feedback may need to sign appropriate confidentiality agreements, at Daiichi Sankyo’s discretion. For any questions, please email: Goldentickets2025@daiichisankyo com 

Daiichi Sankyo:

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical needs. For more information, please visit www.daiichisankyo.com.